Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST
Intensify the inoculation of large-scale bioreactors with a new seed train benchtop module. Discover a CDMO’s experience using the module for low-risk and cost-effective viral production.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1588661&tp_key=a5faada3f1
Event Overview:
The use of adherent-cell cultures for commercial manufacture of advanced therapies requires inoculating large-scale bioreactors with vast amounts of cells. Traditional cell-expansion systems such as plastic flatware are still used for this purpose, but are generally associated with significant aseptic risk, footprint, and production costs. Univercells Technologies has designed a novel benchtop solution to tackle these challenges, delivering reliable, automated, and intensified seed train. Discover how a CDMO has used this new technology, achieving harvest cell densities above 2x109 cells/m² with >90% cell detachment in a small-footprint, low-risk, and cost-effective seed train process.
Key Learning Objectives:
Speakers:
Clément Dumont
Product Manager
Univercells Technology
Clément Dumont, product manager at Univercells Technologies, focuses on the expansion of the scale-X portfolio with intensified bioreactor systems and innovative process analytical technologies. He has experience in the areas of bioprocess development, characterization, and optimization, which he currently applies to the development of the scale-X cell collect module for seed train generation. Clément also has product management experience in the field of medical devices and holds a master’s degree in biomedical engineering from the UCLouvain, Belgium.
Cédric Meeüs
Bioprocess Engineer
Exothera
During his studies (Master’s Degree in Industrial Engineering in Pharmaceutical Biotechnology), Cédric Meeüs joined Univercells to support his thesis regarding the validation and design of the soon-to-be scale-X™ carbo. He then remained in the company and joined its process development team, taking charge of upstream bioprocessing and validating the scale-X carbo and nitro bioreactor systems. Cédric has since joined Exothera and has gathered a wide knowledge of scale-X technology. He also specializes in the areas of gene therapy, viral vectors, recombinant proteins, and the adaptation of suspension cells to fixed-bed bioreactors.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1588661&tp_key=a5faada3f1
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.